Brain Death Diagnosis at an Academic Tertiary Medical Care Center

Sponsor
University Hospital, Basel, Switzerland (Other)
Overall Status
Completed
CT.gov ID
NCT03984981
Collaborator
(none)
100
1
21
4.8

Study Details

Study Description

Brief Summary

The aim of this study is to assess and survey the quality of the process required to diagnose brain death in adult patients. This study of adult patients diagnosed brain dead or suspected of having brain death on the ICUs at the University Hospital Basel will be purely observational.

Condition or Disease Intervention/Treatment Phase
  • Other: Assessment of process required to diagnose brain death in adult patients

Study Design

Study Type:
Observational
Actual Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Brain Death Diagnosis at an Academic Tertiary Medical Care Center
Actual Study Start Date :
Apr 3, 2019
Actual Primary Completion Date :
Dec 31, 2020
Actual Study Completion Date :
Dec 31, 2020

Outcome Measures

Primary Outcome Measures

  1. adherence to the local brain death protocol ( = measurement tool) for the process of brain death diagnosis [single time point assessment at baseline (after suspected brain death)]

    the local brain death protocol ( = measurement tool) requires 1.) exclusion of the following conditions: shock (mean arterial blood pressure > 60 mmHg, lactate < 4 mmol/l) hypothermia (temperature > 35°C) severe acidosis (pH > 7.3) hyperosmolarity (osmolarity < 320 mmol/l) severe electrolyte disorders (sodium > 125 mmol/l, phosphate > 0.3 mmol/l) hypoglycemia (glucose > 4 mmol/l) hyperammonemia (ammonia < 60 mumol/l) uremia (urea < 25 mmol/l) prolonged effects of medication (muscle relaxants, sedatives, recreational drugs) severe hypothyreosis 2.) clinical examination confirming: fixed pupils (dilated or mid-dilated bilaterally) absent vestibulo-ocular reflex absent corneal reflex bilaterally no reaction to painful stimulus bilaterally absence of cough and gag reflex absence of spontaneous breathing (apnea test)

Secondary Outcome Measures

  1. number of physicians involved [single time point assessment at baseline (after suspected brain death)]

    number of physicians involved in the diagnostic procedures

  2. frequency of ancillary tests performed [single time point assessment at baseline (after suspected brain death)]

    frequency of ancillary tests (i.e. transcranial doppler ultrasound, computed tomography, magnetic resonance tomography, digital substraction angiography, electroencephalogram, somatosensory evoked potentials) performed

  3. number of work-ups excluding suspected brain death [single time point assessment at baseline (after suspected brain death)]

    number of work-ups excluding suspected brain death

  4. number of diagnostic work-ups with insufficient performance and/or documentation [single time point assessment at baseline (after suspected brain death)]

    number of diagnostic work-ups with insufficient performance and/or documentation

  5. years of clinical experience of physicians involved [single time point assessment at baseline (after suspected brain death)]

    years of clinical experience of physicians involved in the diagnostic procedures

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patients with suspected and/or diagnosed brain death

  • adults 18 years and over

Contacts and Locations

Locations

Site City State Country Postal Code
1 Clinic for Intensive Care Medicine, University Hospital Basel Basel Switzerland 4031

Sponsors and Collaborators

  • University Hospital, Basel, Switzerland

Investigators

  • Principal Investigator: Raoul Sutter, PD Dr. med, Clinic for Intensive Care Medicine, University Hospital Basel

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier:
NCT03984981
Other Study ID Numbers:
  • 2019-00244; me19Sutter4
First Posted:
Jun 13, 2019
Last Update Posted:
May 26, 2021
Last Verified:
May 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Basel, Switzerland
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 26, 2021